Teaching Video NeurolImage: Clues in Myoclonus Evaluation

When to Consider Sialidosis

Beatriz Vélez Gómez, MD, Silvia Jesús, MD, PhD, Daniel Macías-García, MD, Beatriz Lechon, MD, and Pablo Mir, MD, PhD

Neurology® 2021;97:e2052-e2053. doi:10.1212/WNL.00000000000012464

Correspondence

Dr. Mir
pmir@us.es

Figure Ophthalmic Examination: Cherry-Red Spot

The dilated fundus examination showed bilateral cherry-red spots on the retina. This is a red zone at the center of the macula surrounded by retinal opacification. It is due to the accumulation of different lipids, sphingolipid, or oligosaccharide material in the ganglion cells of the retina.

A 53-year-old woman was presented for the evaluation of visual disturbances, generalized and multifocal myoclonus, and progressive ataxia that began at age 30 years (cf. Video 1). Bilateral cherry-red spots in the macula (figure) and a cortical origin in the EEG-EMG coregistration with back-averaging were observed. Reduced neuraminidase activity in fibroblasts and the homozygous mutation c.403G>A in the *NEU1* gene confirmed the diagnosis of sialidosis type I.

Sialidosis or cherry-red spot–myoclonus syndrome is classified into normomorphic or type I, beginning usually after 20 years old, whereas dysmorphic or type II begins at birth or in early childhood. In both, generalized myoclonus and ataxia can be found. EEG-EMG coregistration may show cortical potential followed by the myoclonus, proving a cortical origin. Differential diagnosis is necessary for other inherited metabolic disorders such as Tay-Sachs disease or Unverricht-Lundborg disease. Cherry-red spots on the retina, cortical myoclonus, and progressive ataxia are essential keys to suspicion.^{1,2}

Study Funding

This research was supported by grants from the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo

MORE ONLINE

Teaching slides

links.lww.com/WNL/B466

Video

From the Unidad de Trastornos del Movimiento (B.V.G., S.J., D.M.-G., P.M., B.L.), Servicio de Neurología y Neurofisiología Clínica, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla/ CSIC/Universidad de Sevilla; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) (S.J., D.M.-G., P.M.), Madrid; and Servicio de Oftalmología (B.L.), Hospital Universitario Virgen del Rocío, Seville, Spain.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, and PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526 and CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, and PE-0186-2019], and the Fundación Alicia Koplowitz. Silvia Jesús has a “Acción B Clínicos-Investigadores” (Action B Clinicians-Researchers) contract [B-0007-2019] funded by the “Consejería de Salud y Familiar,” and Daniel Macías-García has a Río Hortega contract [CM18/00142] funded by the Health Institute Carlos III.

Disclosure

B. Vélez Gómez has received honoraria from Sanofi; S. Jesús has received honoraria from AbbVie, Bial, Merz, UCB, Italfarmaco, and Zambon; D. Macías-García has received honoraria from AbbVie, Teva, and Zambon; B. Lechon reports no disclosures relevant to the manuscript; and P. Mir has served in the advisory boards or received honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva, and Zambon. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

Appendix Authors

Name	Location	Contribution
Beatriz Vélez Gómez, MD	Hospital Universitario Virgen del Rocío, Seville, Spain	Examined the patient, drafted the manuscript, and videotaped
Silvia Jesús, MD, PhD	Hospital Universitario Virgen del Rocío, Seville, Spain	Examined the patient, videotaped, and provided critical review of the manuscript
Daniel Macías-García, MD	Hospital Universitario Virgen del Rocío, Seville, Spain	Examined the patient and provided critical review of the manuscript
Beatriz Lechon, MD	Hospital Universitario Virgen del Rocío, Seville, Spain	Performed ophthalmologic examination
Pablo Mir, MD, PhD	Hospital Universitario Virgen del Rocío, Seville, Spain	Provided critical review of the manuscript and contributed to data acquisition

References

1. Caciotti A, Melani F, Tonin R, et al. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: an overview. *Mol Genet Metab*. 2020;129(2):47-58.
2. Orsini A, Valetto A, Bertini V, et al. The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy. *Seizure*. 2019;71:247-257.

Neurology®

Teaching Video NeuroImage: Clues in Myoclonus Evaluation: When to Consider Sialidosis

Beatriz Vélez Gómez, Silvia Jesús, Daniel Macias-Garcia, et al.
Neurology 2021;97:e2052-e2053 Published Online before print July 14, 2021
DOI 10.1212/WNL.00000000000012464

This information is current as of July 14, 2021

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/97/20/e2052.full
References	This article cites 2 articles, 0 of which you can access for free at: http://n.neurology.org/content/97/20/e2052.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Epilepsy semiology http://n.neurology.org/cgi/collection/epilepsy_semiology Myoclonus http://n.neurology.org/cgi/collection/myoclonus Myoclonus; see Movement Disorders/myoclonus http://n.neurology.org/cgi/collection/myoclonus_see_movement_disorders-myoclonus Peroxisomes http://n.neurology.org/cgi/collection/peroxisomes Retina http://n.neurology.org/cgi/collection/retina
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2021 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.